Ypsomed and CamDiab launch the first system for automated insulin dosing with Abbott’s FreeStyle Libre 3

Press Releases Ypsomed Group

Burgdorf – Ypsomed announces that its mylife Loop is now authorized to work with Abbott’s FreeStyle Libre 3 sensor in Germany. The mylife YpsoPump and the FreeStyle Libre 3, combined with the mylife CamAPS FX algorithm from CamDiab, form an intelligent and automated insulin delivery system (AID) designed to help people with type 1 diabetes to better control their glucose levels and alleviate the burden of daily diabetes management.

Topics:
Innovation & Digital Health

Lees meer...

Ypsomed doubles profits and confirms outlook

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) is on track and achieved consolidated sales of CHF 244.2 million in the first half of the 2022/23 financial year (previous year: CHF 222.6 million). This corresponds to a growth of 9.7% compared with the previous year. At constant currency rates compared to the previous year, this would have represented an increase of around 13%. With this growth, the company has significantly increased its operating profit (EBIT) from CHF 10.5 million to CHF 19.4 million and doubled its net profits to CHF 15.4 million (previous year CHF 7.1 million). Despite a challenging general environment, Ypsomed confirms its positive assessment of future business development and its outlook.

Lees meer...

Ypsomed leaves DiaExpert in new hands and focuses on own products

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) and Mediq have signed an agreement on the sale of DiaExpert. DiaExpert is an established specialist and mail-order retailer for the care of people with diabetes in Germany, specialised in insulin pump therapy. With the sale, DiaExpert will remain as a helping hand for customers and health insurers and will continue its services. Ypsomed is focusing more strongly on the development, manufacture and sale of its own high-quality medical technology products for people with chronic conditions.

Lees meer...

Ypsomed introduces new autoinjector for volumes up to 5.5 ml

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) has developed a new autoinjector platform for liquid medications with volumes ranging from 1.5 to 5.5 ml. The YpsoMate 5.5 is the latest addition to the growing YpsoMate family of devices and is based on the established technology of the YpsoMate 2.25 Pro. YpsoMate 5.5 enables the self-administration of larger volume medications for treating cancer, rare and autoimmune diseases.

Topics:
Innovation & Digital Health

Lees meer...

Ypsomed partners with leading digital therapeutics innovator Sidekick Health to improve therapy outcomes

Press Releases Ypsomed Group

Burgdorf – Ypsomed (SIX: YPSN) and Sidekick Health today announced a collaboration to extend Ypsomed’s device and SmartServices offering by implementing a self-injection module in Sidekick’s proven digital therapeutics solution. The combination of Ypsomed’s devices with Sidekick’s digital health behavioural economics and gamification expertise will form a unique solution delivering an engaging and personalized patient experience to people with chronic conditions, as well as a turn-key, best-in-class digital therapy management system to pharmaceutical customers.

Topics:
Innovation & Digital Health

Lees meer...